Investment Banking

Overview

Investment Banking for Life Sciences and Healthcare

Dr. David H. Crean, Ph.D., MBA, leads Cardiff Advisory, bringing 30+ years in M&A, partnering, and capital advisory across biopharma and healthcare. He has completed over 50 transactions and advised executives and investors on strategic, financial, and corporate development initiatives.

 

Cardiff Advisory provides end-to-end transaction support to ensure every M&A process achieves maximum value and minimal disruption.


Our structured 6–9 month process has guided dozens of companies through successful growth or exit transactions.

0 +
Years of Combined Experience

In investment banking and
corporate development.

0 +
Transactions Completed

Across buy-side, sell-side, and cross-border deals in healthcare and life sciences.

Overview

Investment Banking for Life Sciences and Healthcare

Dr. David H. Crean, Ph.D., MBA, leads Cardiff Advisory, bringing 30+ years in M&A, partnering, and capital advisory across biopharma and healthcare. He has completed over 50 transactions and advised executives and investors on strategic, financial, and corporate development initiatives.

Cardiff Advisory provides end-to-end transaction support to ensure every M&A process achieves maximum value and minimal disruption.

Our structured 6–9 month process has guided dozens of companies through successful growth or exit transactions.

0 +
Years of Combined Experience

In investment banking and
corporate development.

0 +
Transactions Completed

Across buy-side, sell-side, and cross-border deals in healthcare and life sciences.

Services

1. Transaction Structuring

Design and execute deal structures that optimize valuation, mitigate risk, and accelerate closing.

4. Negotiation Support

Leverage decades of experience to secure optimal terms, pricing, and contingencies.

2. Market Positioning

Develop a compelling narrative that resonates with buyers, investors, and partners.

5. Post-Deal Integration Advisory

Ensure cultural and operational alignment for long-term success after the close.

3. Due Diligence Management

Streamline diligence processes and ensure transparency for both sides of the table.

Services

1. Transaction Structuring

Design and execute deal structures that optimize valuation, mitigate risk, and accelerate closing.

4. Negotiation Support

Leverage decades of experience to secure optimal terms, pricing, and contingencies.

2. Market Positioning

Develop a compelling narrative that resonates with buyers, investors, and partners.

5. Post-Deal Integration Advisory

Ensure cultural and operational alignment for long-term success after the close.

3. Due Diligence Management

Streamline diligence processes and ensure transparency for both sides of the table.

Case Studies

MedGenix

$100M sell-side M&A transaction with global pharma acquirer.

TheraCell

$75M divestiture of therapeutic assets.

NeuroVista

$40M acquisition of AI diagnostics company.

OcuMed

$65M merger in ophthalmic devices

AstraPharm

$90M buy-side advisory for specialty pharma acquisition.

Dermalynx

$25M strategic sale to a medical aesthetics firm.

ReproMed

$50M divestiture in women’s health.

CardioNova

$120M merger and
restructuring.

BioImmunix

$45M cross-border M&A with EU partner.

Case Studies

MedGenix

$100M sell-side M&A transaction with global pharma acquirer.

TheraCell

$75M divestiture of therapeutic assets.

NeuroVista

$40M acquisition of AI diagnostics company.

OcuMed

$65M merger in ophthalmic devices

AstraPharm

$90M buy-side advisory for specialty pharma acquisition.

Dermalynx

$25M strategic sale to a medical aesthetics firm.

ReproMed

$50M divestiture in women’s health.

CardioNova

$120M merger and
restructuring.

BioImmunix

$45M cross-border M&A with EU partner.

Partners

BA Securities, LLC
Oppenheimer
Credit Suisse
Takenaka Partners
Deloitte
Procopio LLP

Partners

BA Securities, LLC
Oppenheimer
Credit Suisse
Takenaka Partners
Deloitte
Procopio LLP

Insights

M&A success hinges on preparation and positioning — not just timing.
Our insight: companies that treat M&A readiness as a strategic discipline consistently achieve premium valuations.

Insights

M&A success hinges on preparation and positioning — not just timing.
Our insight: companies that treat M&A readiness as a strategic discipline consistently achieve premium valuations.

Connect

Ready to explore M&A or partnership options?

Connect with Cardiff Advisory to assess your company’s market position and identify the right strategic alternatives.

Connect

Ready to explore M&A or partnership options?

Connect with Cardiff Advisory to assess your company’s market position and identify the right strategic alternatives.